"One of today's leaders in investor relations and shareholder services"

SC Daily Signup

International Stem Cell Corporation (OTCBB: ISCO)

Dr. Simon Craw, Executive Vice President of International Stem Cell Corporation (OTCBB: ISCO), called into SmallCapVoice.com to go over the ISCO’s business model, market and recent news. International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

Share/Bookmark
BBB Accredited Business since 11/23/2005
Social
Visit Us On TwitterVisit Us On FacebookVisit Us On YoutubeCheck Our FeedVisit Us On LinkedinVisit Us On Pinterest
QualityStocks Blog
Sponsors